What is the VMT of Ocriplasmin and what does it specifically refer to?

One of the core indications that Ocriplasmin is mainly used to treat is VMT, which is Vitreomacular Traction. VMT is a fundus disease that usually occurs at the junction of the vitreous body and macula. When the vitreous gradually liquefies and partially detaches with age or structural changes in the vitreous, traction may occur if there is abnormal adhesion to the macular area. This traction force can lead to changes in the shape of the macula, which can lead to vision loss, deformation, and even the development of macular holes.

Clinically, The symptoms of VMT include visual distortion, blurred central vision and difficulty reading, which have a great impact on patients' quality of life. The traditional solution is to directly relieve traction through vitrectomy surgery, but the surgery requires a high level of technology and involves certain risks. The emergence of Oak plasmin makes it possible to separate the vitreous body and macula through intravitreal injection of drugs, thereby relieving the traction without surgery. This pharmacological treatment is particularly valuable for some patients with early or moderate VMT.

From a mechanism perspective, Oak plasmin is a recombinant proteolytic enzyme that can cleave extracellular matrix components such as fibronectin and laminin, which play a key role in the adhesion between the vitreous body and the macula. Through this molecular-level intervention, the drug can selectively weaken the bond between the vitreous and macula, thereby promoting natural posterior vitreous detachment.

In international clinical experience, the effectiveness of Oakplasmin in the treatment ofVMT has been confirmed, but doctors also emphasize the importance of patient screening. Not all patients with VMT are suitable for this drug. For example, those with large macular holes or severe retinopathy may have limited efficacy. Therefore, in clinical application, it is necessary to use imaging methods such as OCT to make accurate judgments and select appropriate patients to maximize the drug effect.

Reference materials:https://www.drugs.com/cdi/ocriplasmin.html